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ABSTRACT
Background: MicroRNAs are a class of negative regulators of 
gene expression. Evidences indicate that miRNAs involved in the 
pathogenesis of New type 2 diabetes(NT2D)  through decrease the 
expression of the genes secreting insulin and increase expression of 
insulin secretion suppressing ones, as well as exocytosis, incorporate 
in New type 2 diabetes . In this study, we evaluated the expression 
level of miR-135 in plasma sample of those prone to susceptible 
diabetes and New type 2 diabetes patients compared to the control 
group.
Methods: Subsequently to evaluation of biochemical parameters such 
as (TG, TC, HDL and LDL) in susceptible diabetes, New type 2 diabetes 
and control group, miR-135a level was measured  by qRT-PCR in 
the  plasma samples and  results were analyzed by  Stata and REST 
softwares.
Results: We identified a significant increase in miR-135a expression in 
New type 2 diabetes and susceptible diabetes samples compared to the 
control group. AUC in ROC curve analysis was 1.1 respectively (confidence 
interval of 1.0-1.0) for NT2D and susceptible diabetes group, the best 
cut-off points for diagnostics in diabetics and susceptible diabetes were 
2.00 and 1.02. The optimum sensitivity and specificity for both groups 
was 100 and 100. Results confirmed the test for 100% confidence in 
healthy, susceptible diabetes and New type 2 diabetes subjects.
Conclusion: It seems that plasma level of miR-135a can be a desirable 
biomarker to differentiate T2DM diabetics from the control group.
Cite This Article: Sarookhani, M.R., Honardoost, M., Foroughi, F., Monfared, Y.K. 2018. Plasma miR-135a; a potential biomarker for diagnosis of 
new type 2 diabetes (T2DM)Bali Medical Journal 7(2): 296-301. DOI:10.15562/bmj.v7i2.880
Plasma miR-135a; a potential biomarker for 
diagnosis of new type 2 diabetes (T2DM)
Mohammad Reza Sarookhani,1 Maryam Honardoost,2 Farshad Foroughi,3  
Yousef Khazaei Monfared4*
INTRODUCTION
Diabetes is the most prevalent endocrine disorder, 
and it includes several groups of metabolic disor-
ders (such as the lack of or insulin insufficiency, 
and high absolute levels of glucagon) whose 
common feature is a hyperglycemic phenotype.1 
Hyperglycemia mostly occurs as a result of complex 
reactions between genetic, environmental, and life-
style elements. However, it is also affected by factors 
such as insulin decrease, decrease insulin consump-
tion, and increase insulin production.2 
According to World Health Organization 
(WHO), the prevalence of diabetes was about 
400  million people in 2013. Studies reported that 
this figure will increase at a fast pace and predicted 
to be around 600 million individuals by 2035.3 
There are four categories of diabetes: type 1 diabe-
tes, type 2 diabetes, gestational diabetes, and other 
specific types. The most prevalent is type 2 diabetes 
with 85-90 percent. It is mostly observed among 
adults over-30 and those with obesity.1
One of the most common causes of type 2 diabe-
tes is insulin resistance (no or decreased response 
to the normal levels of insulin) and abnormal 
secretion of insulin. Insulin resistance results from 
defected insulin signaling, a change in the target 
protein or gene expressions, metabolic defects or 
interference with other hormones.4
Other factors leading to type 2 diabetes are 
miRNAs, a group of regulatory RNAs (~19-22 nt) 
that function to modulate  various biological 
processes such as tissue development and metab-
olism.4,5 They have fundamental roles such as in 
pancreas evolution; regulation of insulin secretion 
driven by glucose; catabolism of amino acids; 
formation of fatty acids in the liver; and differentia-
tion of fat tissue, myoblast, and myogenes. Binding 
to 3’-UTR in one or more target mRNA, miRNAs 
terminates the process of translation, therefore 
suppressing gene expression.5 Recently, evidence 
indicates that miRNAs are involved in the patho-
genesis of  T2DM  through decreasing the expres-
sion of insulin-secreting genes and increasing the 
expression of insulin suppressing genes.6
On our previous project, we identified that the 
overexpression of miR-135a in vitro induced insulin 
resistance by targeting insulin signaling pathway.7 
Henceforth, we hypothesized that miR-135a could 
be an ideal blood-based biomarker for type 2 diabe-
tes detection since miRNAs may have exceptional 
stability in plasma.8
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The present study aims at investigating the 
expression level of miR-135a in the plasma sample 
of those susceptible individuals and  newly diag-
nosed type 2 diabetes patients and compare them 
to the control group.
MATERIAL AND METHOD
Subject characteristics
A total of 120 subjects were included in this 
case-control study. The subjects were divided into 
4 groups, which were healthy individuals, people 
with a newly diagnosed type 2 diabetes in the last 
6 months and not taking any hypoglycemic drugs, 
people with impaired fasting glucose (IFG), and 
people with impaired glucose tolerance (IGT). 
The study took place in the Center of Metabolic, 
Qazvin, Iran. The ethical code was REC.1394.191 
granted from Qazvin Medical University. Informed 
consent was taken from all the subjects.
Subjects who had malignant tumors, cardio-
vascular diseases, nephropathy, and taking any 
hypoglycemic drugs longer than 6 months were 
excluded because they would have affected miRNA 
expressions.  
Laboratory examinations
Diabetic and pre-diabetic (IFG, IGT) subjects were 
confirmed with the use of WHO 1998 criteria.9 
The criteria were based on the serum glucose level, 
the fasting plasma glucose test (FPG) which were 
drawn after 12 hours of fasting, and oral glucose toler-
ance test (OGTT) test. Subjects who were confirmed 
by OGTT to have FPG > 7.0 mmol/L and 2 hours 
plasma glucose (2hPG) > 11.1 mmol/L were diag-
nosed as newly diagnosed type 2 diabetes patients. 
Meanwhile, subjects with FPG 5.6–6.9 mmol/L, and 
2hPG 7.8 mmol/L were diagnosed as susceptible 
patients (IFG or IGT). Biochemical parameters such 
as triglyceride (TG), total cholesterol (TC), high-den-
sity lipoprotein (HDL), and low-density lipoprotein 
(LDL) were investigated in all subjects.
RNA isolation and Quantitative Real-time 
PCR
Peripheral blood was placed in an EDTA contain-
ing tube and centrifuged at 2.000g for 6 minutes. 
After being centrifuged, the blood was aliquoted 
and stored at -80°C until miRNA detection. 
Total RNAs were then extracted from 250 µl of 
plasma using TRK- 1001 (LC-Bio, USA). According to 
the protocol, 5 µL of plasma RNA containing miRNA 
was reverse transcribed to cDNA. The reverse tran-
scription solution system consisted of 5 µl total RNA, 
1 µL M-MLV Buffer, 1 µL M-MLV, 0.5 µL dNTP, and 
0.5 µL RRI (Reverse Transcriptase M-MLV (RNase 
H-), TAKARA, CHINA). Reverse transcription reac-
tion in Real Time PCR instrument (MyGene L96G, 
LongGene, CHINA). Real-time PCR was performed 
using Platinum SYBR Green qPCR SuperMix-UDG 
(Invitrogen: 11733-038). RNU6B, which was more 
stable in serum and rarely changed in different 
people, was used as an internal control gene, accord-
ing to the Applied Biosystems Application Note.10,11 
All reactions were run in triplicate.
Statistical analysis
Means and standard deviations of demographic 
and background variables in each group were 
calculated. We also analyzed mean and 95% CI 
of miR-135a. To assess the association between 
miR-135a and independent variables, a simple 
linear regression model was used. Variables with 
p-value <0.2, based on the R-square values, were 
included in a multiple-linear-regression model. 
We also examined multiple collinear ties and kept 
the most representative variable as a surrogate. To 
identify the pre-diabetics and T2DM, nonparamet-
ric analysis of ROC curve was used. The statistical 
analyses was done using the Stata software (ver. 14; 
College Station, Texas, USA). In order to analyze 
miR-135a gene expression, the REST 2009 software 
(Qiagen, Hilden, Germany), an independent algo-
rithm plotting the outcome analysis for each gene 
as well as distributions along with the whisker box 
diagram, was utilized.
RESULTS
Out of 120 subjects, 48% of the population were 
men and 52% were women. Means of ages (± SD) 
of the control, susceptible diabetes, and newly 
diagnosed type 2 diabetes group were 24.7 (2.8), 
39 (38.8), and 53.8 (5.6), respectively. Findings also 
revealed that body mass index (BMI) was higher in 
newly diagnosed type 2 diabetes than other groups 
(Table 1).
Results from REST software indicated a signif-
icant increase in an up-regulation of miR-135a in 
Table 1 Subject characteristics
Characteristics Control (n = 30) Pre-Diabete (n = 60) T2DM (n = 30)
Male 14 ± 46.4 20 ± 33.3 14 ± 46.6 
BMI (kg/m2) 22.5 ±1.9 26.8 ± 0.4 30.0 ± 1.0 
Age 24.7± 2.8 39 ± 38.8 53.8 ± 5.6 
TG 91.7 ± 6.2 126.9 ±4.3 221.7 ± 18.9 
TC 124.0 ± 5.2 214.4 ± 16.5 260.9 ± 9.4 
HDL 81.6 ± 4.6 40.0 ±31.7 30.2 ±2.3 
LDL 130.9 ±185.0 146.1 ± 8.8 175.5 ±7.0 
Test score 0.9 ± 0.06 1.3 ±0.2 3.6 ±0.7 
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Table 2  Mean and 95% CI of miR-135a by subjects characteristics
Characteristics Sub Group n of participants (%) Mean (95% CI)* Regression coefficients P value
Sex Men 48 (40.0) 1.8 (1.5 – 2.2) 1
Women 72 (60.0) 1.8 (1.5 – 2.0) -0.9 0.659
Group Control 30 (25.0) 0.9 (0.8 – 0.9) 1
Susceptible 60 (50.0) 1.3 (1.3 – 1.4) 0.4 < 0.001
Newly diagnosd type 2 diabetes 30 (25.0) 3.6 (3.4 – 3.9) 2.7 < 0.001
Age Under 30 29 (24.1) 0.9 (0.8 – 0.9) 1
30 – 50 73 (60.8) 1.7 (1.5 – 1.9) 0.8 < 0.001
Over 50 18 (15.0) 3.6 (3.2 – 4.0) 2.7 < 0.001
BMI Normal 29 (24.1) 0.9 (0.8 – 0.9) 1
Overweight 78 (65.0) 1.8 (1.6 – 2.4) 0.9 < 0.001
Obese 13 (10.8%)? 3.9 (3.5 – 4.3) 3.0 < 0.001
LDL < 100 18 (15.0) 0.9 (0.8 – 0.9) 1
100 – 129 11 (9.1) 0.9 (0.9 – 0.9) 0.04 0.864
130 – 159 56 (46.6) 1.3 (1.3 – 1.4) 0.4 0.007
> 160 35 (29.1) 3.3 (2.9 – 3.7) 2.4 < 0.001
HDL < 40 59 (49.1) 2.5 (2.2 – 2.8) 1
40 – 50 31 (25.8) 1.3 (1.3 – 1.4) -1.1 < 0.001
50 – 60 11 (9.1) 0.9 (0.8 – 0.9) -1.6 < 0.001
> 60 19 (15.8) 0.9 (0.8 – 0.9) -1.6 < 0.001
TG < 150 90 (75.0) 1.2 (1.1 – 1.2) 1
150 – 199 4 (3.3) 2.8 (2.1 – 3.5) 1.6 < 0.001
200 – 500 26 (21.6) 3.8 (3.5 – 4.0) 2.6 < 0.001
TC < 200 47 (39.1) 1.0 (0.9 – 1.1) 1
200 – 240 43 (35.8) 1.3 (1.3 – 1.4) 0.3 0.001
> 240 30 (25.0) 3.6 (3.4 – 3.9) 2.6 < 0.001
Mean of miR-135a expression
Table 4 ROC curve analysis
Diseased No of Obs Cut-Point Sensitivity Specificity Accuracy Area ROC CI 95%
Pre diabetes 60/30 1.02 100 100 100 1.0 1.0 – 1.0
Newly diagnosed T2DM 30/30 2.0 100 100 100 1.0 1.0 – 1.0
Table 3  Multiple linear regression model to assess the association between background variables and miR-135a
Characteristics Sub group Regression coefficients (95% CI) P value
Sex Men 1
Women 0.05 (-0.1 – 0.2) 0.477
Age Under 30 1
30 – 50 -0.07 (-0.9 – 0.7) 0.855
Over 50 -0.2 (-1.1 – 0.6) 0.571
Group Control 1
Pre - diabetes 0.5 (-0.3 – 1.3) 0.212
Newly T2DM 2.9 (2.1 – 3.8) < 0.001
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newly diagnosed T2DM and pre-diabetes compared 
to the control group (p<0.05) (Figure 1).
Crude model analysis showed that there was a 
correlation between miR-135a expression and age, 
BMI, TG, TC and LDL. However, a negative correla-
tion between  miR-135a and HDL level was also 
observed. A significant difference between control 
and susceptible groups was shown, which means 
miR-135 may have prognostic value (Table 2).
Multivariate linear regression showed that 
the mean of test scores (regression coefficient) of 
miR-135a was 2.9 folds higher in the newly diag-
nosed T2DM group than the control group, after 
eliminating variables such as age, gender and BMI 
(CI 95%, 1.5-3.9). This difference was statistically 
significant (Table 3). 
A significant difference between pre-diabetes 
and the control groups for miR-135a score means 
(Figure 1) was also found. However, we did not 
find any significant difference (regression coef-
ficient=0.5; 95% CI= -0.3 – -1.3), even with the 
highest score means of miR-135a, after adjusting 
the confounding factors in the multivariate model 
(Table 3).
AUC in ROC curve analysis was 1.0  (95%  CI 
1.0-1.0) for newly diagnosed T2DM and 
susceptible diabetes, the best cut-off points for 
diagnostics in diabetes and pre-diabeteswere 2.00 
and 1.02  respectively (Table 4).
The optimum sensitivity and specificity for both 
groups were 100 and 100. Results confirmed the 
test for 100% confidence in healthy,  pre-diabetes 
(Figure  2A) and newly diagnosed T2DM 
subjects (Figure 2B).
DISCUSSION
Recently, there have been a lot of investigations on 
the presence of miRNA in the serum and plasma 
as a new strong noninvasive method to diagnose 
cancer, cardiovascular diseases,  and metabolic 
illnesses such as diabetes.12 The  first report of 
miRNA  involvement in T2DM  was published 
by Poy, et  al. in 2004.13  Based on the developing 
evidence, T2DM is associated with alterations of 
miRNA level in the  insulin-target tissues, serum, 
or plasma sample. Therefore, it can be used as a 
predictive biomarker of diabetes.14,15 In an experi-
mental study by Yong et al., miR-23a could be used 
as a plasma biomarker in diabetic patients.12 Other 
studies on plasma samples of newly diagnosed 
diabetes also showed that miR-146a, miR-126, and 
miR-7 had a significant level of expression in the 
newly diagnosed diabetes but not in susceptible 
diabetes.16,17 Recent findings indicate that miR-135 
plays a few functional roles in the occurrence of 
lung cancer, gastric, colorectal, as well as Hodgkin’s 
lymphoma syndrome.18 Another study by Feng He 
et al. also reported that miR-135 involved in diabe-
tes occurrence. It also stated that its higher expres-
sions in diabetic nephropathy rats would lead to 
renal fibrosis.19 In an Indian study, authors claimed 
that higher expression of miR-135 in musculoskel-
etal system of diabetic rats reduced expressions of 
the protein-producing insulin receptors, which was 
related to type-2 diabetes.20 
Our results of biochemical parameters like TG, 
TC, HDL, LDL in newly diagnosed type 2 diabe-
tes patients had a significant increase compared to 
pre-diabetes and the control group 1 . These results 
were consistent with Kong et  al., who reported 
significant differences among biochemical param-
eters in the diabetics compared to the control 
group. However, their study showed that there 
was no significant difference in BMI between the 
two groups. Meanwhile, we found a higher BMI in 
newly diagnosed type 2 diabetes in crude analysis. 
Nonetheless, Ying Rong, et al. reported that newly 
diagnosed type 2 diabetes had higher levels of TG, 
TC, and BMI than the control group.17
In our prior in vitro project, we recognized 
that miR-135a overexpression  in C2C12 cell line 
Figure 1  Relative expression of miR-135a in newly T2DM and pre-diabetes 
compared to the control group
Figure 2  ROC curve analysis; A: Discrimination between the cases of 
 pre-diabetes patients and control group; B: Discrimination between 
the cases of newly T2DM patients and control group
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induced insulin resistance through protein signal-
ing involved in glucose uptake. Interestingly, our 
present study showed that miR-135a expression 
level has significantly increased in the plasma 
sample of newly diagnosed type 2 diabetes patients.7 
Agarwal et al. also found an increased miR-135 level 
in diabetic skeletal muscle and its downregulation 
in vivo improved glucose tolerance.21 Otherwise, 
Honardoost et  al. reported   that   in vitro   induc-
tion  of miR-135a had a negative effect on insulin 
action by targeting  key components of the insulin 
signaling pathway.7
Abnormality of human miR-135a expression, 
which was shown in our present study, may have 
a  role in reducing insulin-stimulated glucose 
disposal and subsequently may be a hint of a 
type 2 diabetes process (Table 3, p-value>0.001). 
Furthermore, ROC curve analysis indicated that 
the best cut-off points with optimum sensitivity 
and specificity to diagnose T2DM and pre-diabetes 
were 2.00 and 1.02 (Figure 2, Table 4). Consequently, 
evaluation of miR-135a plasma level has a valuable 
potential to be used as a diagnostic biomarker. 
Nevertheless, based on our present data, despite 
the different expression level of miR-135a in 
pre-diabetes and control crude model, we found 
no statistically significant difference of the figures 
after adjusting the covariates (Table 3). It seems 
that evaluation of miR-135a as a prognostic value in 
pre-diabetes needs a further investigation in a larger 
population. In some studies, miRNA expression 
in pre-diabetes had no difference with the control 
groups.11,22-24 It was partly inconsistent with our 
study because of the differences in samples taken 
either from plasma or from serum since miRNAs 
expressions are different in serum from plasma.25  
CONCLUSION
To sum up, plasma level of miR-135a can be a desir-
able biomarker to identify a newly diagnosed type 2 
diabetes. However, it cannot be used in a suscepti-
ble patient. Therefore another screening method is 
needed to confirmed susceptible individuals.
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